SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community rallies in anticipation of the upcoming 4/20 cultural event, with proponents highlighting its "culture first" mission to advance global cannabis legalization on the Solana blockchain, framing it as "like Bitcoin but way higher" amidst discussions of both potential and skepticism.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is gaining significant attention and showing strong resilience, often posting gains even as broader markets experience downturns, cementing its perception as a "flight to safety" asset. The community is actively discussing its consistent dividend growth and potential benefits from sector rotation away from tech, though some investors anticipate a pullback due to an extended valuation.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as it announced its first commercial ZEVASKYN patient treatment and secured a permanent J-code for smoother reimbursement, reinforcing its projected path to profitability in the first half of 2026. The community highlights the stock's deep undervaluation against its cash position and immense revenue potential, fueling speculation of a re-rating as patient treatments for the rare disease gene therapy ramp up.

WorldFinancial

WLFI is actively discussed due to a US House probe into its $500 million investment deal with an Abu Dhabi-affiliated entity, sparking conflict-of-interest concerns, while supporters point to its USD1 stablecoin's increasing market cap, a significant Binance integration, and anticipated Real World Asset (RWA) platform. The community remains divided between those who see it as a legitimate project tied to the Trump family's vision for decentralized finance and those who label it a pump-and-dump scheme.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following positive Q4 earnings that beat expectations and the announcement of a strategic collaboration with SDCL for up to 450 MW of fuel cell power for AI data centers. The community is actively discussing FCEL's potential to capitalize on the immense demand for on-site energy solutions in the rapidly expanding AI sector, drawing comparisons to competitors' successful data center initiatives.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's is seeing increased conversation after its Q4 earnings outperformed expectations, fueled by a return to positive comparable sales and robust Pro segment growth, which offsets persistent DIY and housing market pressures. The company's strategic acquisition of Foundation Building Materials and cautious guidance for the upcoming year are leading to community debate about its resilience and competitive positioning against Home Depot.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending following a downward revision to its full-year outlook after missing Q3 earnings, citing soft big-ticket demand and macroeconomic headwinds, which is intensifying community debate around its short-term trajectory despite ongoing strategic investments in its Pro ecosystem and digital initiatives.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is a focal point of investor debate after its challenging earnings report and substantial dividend cut sparked widespread concern over the agricultural sciences company's financial health and leadership, though a segment of the community sees the stock as deeply oversold with potential for a rebound or strategic acquisition.

SSgA Active Trust - State Street Industrial Select Sector SPDR ETF

Industrial Select Sector SPDR Fund

XLI is trending, hitting new highs as market participants rotate into industrials, bolstered by strong manufacturing data and robust earnings forecasts, with community discussion highlighting an "American Industrial Revival" and continued technical strength.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending following a recent regulatory filing signaling a potential Berkshire Hathaway stake sale, which has sparked intense community debate while reinforcing its position as a defensive "cash cow" with strong earnings, a substantial share buyback program, and an appealing dividend yield amid market rotation to safety. Investors are discussing the company's intrinsic value and potential for further upside from an anticipated stock split.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 68.0% during the third quarter, according to the company in its most recent 13F...

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5.26% and -0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6% - Time to Sell?

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.6% - Here's Why...

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold

Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>The trial is for the use of Nexiguran Ziclumeran (Nex-Z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.</li><li>The Phase 3 trial was suspended after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue.</li><li>The decision clears the way for Intellia to resume patient enrollment in the study.</li></ul>Shares of Intellia Therapeutics (NTLA) gained more than 13% on Tuesday morning as the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial of Nexiguran Ziclumeran (Nex-Z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare nerve-damaging disease.A clinical hold is a delay or suspension of an ongoing clinical trial due to serious safety concerns.<h2 class="st-heading-2">Why Did FDA Suspend The Trial?</h2>The clinical hold was imposed in late October 2025 after a patient dosed with Nex-Z in a related trial experienced a severe liver enzyme issue that met the protocol-defined pausing criteria. Since then, Intellia has worked with the FDA to implement study modifications, including enhanced monitoring of liver-related lab tests.“With the clinical hold for MAGNITUDE-2 lifted, our team is focused on resuming patient enrollment as quickly as possible as we seek to advance this potential one-time treatment option for people living with ATTRv-PN,” said John Leonard, Intellia’s President and CEO.MAGNITUDE-2 is a randomized placebo-controlled study assessing the safety and effectiveness of Nex-Z in patients with ATTRv-PN. Following a protocol update, Intellia increased target enrollment to about 60 patients.<h2 class="st-heading-2">What’s Next?</h2>The decision clears the way for Intellia to resume patient enrollment in the study. Intellia said discussions with the FDA are ongoing regarding the separate MAGNITUDE Phase 3 trial of Nex-Z in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and the company will provide an update once a path forward is finalized.Nex-Z is a gene-editing therapy designed to permanently inactivate the TTR gene, which is key in producing a protein called transthyretin. The program has received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, highlighting its potential to address serious unmet medical needs.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘high’ message volumes. <a href="https://stocktwits.com/symbol/NTLA">NTLA</a> was among the top trending tickers on the platform at the time of writing.One user believes the development should be good for the sector.<stembedurl>https://stocktwits.com/FredGS/message/642984565</stembedurl>Another user expects the stock to cross $20 by the end of the trading session. It is currently trading close to $15.<stembedurl>https://stocktwits.com/BrokersNY/message/642985076</stembedurl>The stock has gained nearly 50% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/what-triggered-qbts-stock-s-pre-market-rally-today/cmyaCXDR4LL">What Triggered QBTS Stock’s Pre-Market Rally Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About?

The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with Nex-Z 

Equity

AI Hits the Factory Floor, Defense Wins Get Bigger, and Gene Editing Regains Momentum

This morning’s news flow highlights how innovation is translating into execution across robotics, industrial automation, defense, and life sciences.

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.9% - Time to Buy?

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.9% - Still a Buy...

Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 11.8% in the 3rd quarter, according to the company in its most recent 13F filing...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$12.28
Prev Close	$11.09
Open	$11.32
Dividend Yield	0.00%
50-Day Moving Average	$10.72
Beta	1.73
Avg. Volume	6.9M
PE Ratio	-2.88

52-Week High	$28.25
52-Week Low	$5.90
Market Capitalization	$1.42B
EPS (Annual)	-$5.25
Price to Book	1.90
Revenue Per Employee	$143,615.39
Enterprise Value/EBITDA	N/A

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News

NTLAIntellia Therapeutics Inc